ArtNr |
S2246-10000 |
Hersteller |
Selleckchem
|
CAS-Nr. |
154229-18-2 |
Menge |
10 g |
Quantity options |
100 mg
1 g
10 g
10 mM/1 mL
25 mg
5 mg
5 g
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Smiles |
CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CC=C4C5=CN=CC=C5)C)C |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
CB7630 Acetate |
Similar products |
Abiraterone |
Lieferbar |
|
Storage Conditions |
2 years -80 in solvent |
Molecular Weight |
391, 55 |
Administration |
Administered via s.c. |
Animal Models |
Male NOD/SCID mice with LAPC4 cells |
Cell lines |
LNCaP and VCaP cells |
Clinical Trials |
Abiraterone has entered in a phase II clinical trial in the treatment of castration-resistant prostate cancer and stage IV prostate cancer. |
Concentrations |
0 uM -10 uM |
Dosages |
0.5 mmol/kg/d |
Formulation |
0.1 mL 5% benzyl alcohol and 95% safflower oil solution |
IC50 |
72 nM [1], 72 nM [1], 72 nM [1], 72 nM [1], 72 nM [1], 72 nM [1] |
In vitro |
Abiraterone shows a good complexation with the heme iron only in SM1. [1] Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. Abiraterone also blocks 3beta-hydroxysteroid dehydrogenase (3betaHSD), an enzyme that is absolutely required for the synthesis of biologically active androgens. Abiraterone inhibits conversion of DHEA to delta4-androstenedione. Abiraterone inhibition of 3betaHSD blocks DHT synthesis and the androgen receptor response. Abiraterone inhibits the conversion of delta5-androstenediol to testosterone. [2] Abiraterone inhibits C17, 20-lyase, with an IC50 of 5.8 nM, in rat testis microsomes. Abiraterone significantly inhibits testosterone secretion ( 48%) and in turn increases LH concentration (192%). [3] Abiraterone inhibits in vitro proliferation and AR-regulated gene expression of AR-positive prostate cancer cells, which could be explained by AR antagonism in addition to inhibition of steroidogenesis. [4] |
In vivo |
At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.[2] Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate.[6] |
Incubation Time |
24 hours and 96 hours |
Kinase Assay |
[3], C17, 20-lyase activity assay, Microsomes are diluted to a final protein concentration of 50 ug/mL in the reaction mixture which contains 0.25 M sucrose, 20 mM Tris-HCl (pH 7.4), 10 mM G6P and 1.2 IU/mL G6PDH. After equilibration at 37 C for 10 minutes, the reaction is initiated by addition of betaNADP to obtain a final concentration of 0.6 mM. Prior to the distribution of 600 uL of the reaction mixture in each tube, test compounds are evaporated to dryness under a stream of nitrogen and then are incubated at 37 C for 10 minutes. After incubation with Abiraterone, 500 uL of the reaction mixture is transferred to tubes containing 1 uM of the enzyme substrate, 17OHP. After a further 10 minutes incubation, tubes are placed on ice and the reaction is stopped by addition of 0.1 ml NaOH 1N. Tubes are deep-frozen and stored at -20 C until assayed for delta4A levels. A delta4A RIA is developed and automated on a microplate format in our laboratory using a specific antibody against delta4A and instructions provided by Biogenesis. The separation of free and bound antigen is achieved with a dextran-coated charcoal suspension. After centrifugation, aliquots of the clear supernatant are counted in duplicates in a liquid scintillation counter. The delta4A concentrations of unknown samples are determined from the standard curve. The detection limit is 0.5 ng/mL and the within and between assay coefficients of variation are 10.7 and 17.6%, respectively at an assay value of 13 ng/mL. The rate of enzymatic reaction is expressed as pmol of delta4A formed per 10 minutes and per mg of protein. The value of maximum activity without inhibitor (control) is set at 100%. The IC50 values are calculated using non-linear analysis from the plot of enzyme activity (%) against log of inhibitor concentration. |
Method |
LNCaP and VCaP cells are seeded in 96-well plates and grown in CSS-supplemented phenol red–free or FBS-supplemented media for 7 days. Cells are treated with Abiraterone at 24 hours and 96 hours after plating and cell viability is determined on day 7 by adding CellTiter Glo and measuring luminescence. |
Solubility (25C) |
DMSO 20 mg/mL, Water <1 mg/mL, Ethanol 78 mg/mL |
Information |
Abiraterone Acetate is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM in a cell-free assay. Abiraterone acetate is an oral androgen biosynthesis inhibitor. |
Chemical Name |
(3S, 8R, 9S, 10R, 13S, 14S)-10, 13-dimethyl-17-(pyridin-3-yl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate |
Features |
Abiraterone is a drug used in castration-resistant prostate cancer. |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.